Loading
NASDAQHealthcareMedical - Diagnostics & Research
Latest quote
$23.12
−$0.07 · -0.30%
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
Previous close
$23.12
−$0.07 · -0.30%
After-hours
$23.12
$0.00 · 0.00%
Oct 9, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
Day range
Current $23.12
52-week range
Current $23.12
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
80
Undervalued
Sentiment
61
Bullish
Risk
58
Elevated Risk
Momentum
50
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
Day range
Current $23.12
52-week range
Current $23.12
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 24.05M USD | 15.97M USD | 15.2M USD | 9.41M USD | 8.85M USD |
| Cost of goods sold | 13.34M USD | 8.41M USD | 9.18M USD | 6.9M USD | 6.46M USD |
| Gross profit | 10.71M USD | 7.56M USD | 6.02M USD | 2.51M USD | 2.39M USD |
| Research and development | — | 2.3M USD | 2.7M USD | 2.7M USD | 2.3M USD |
| Selling, general, and administrative | — | 11.78M USD | 13.64M USD | 15.31M USD | 12.01M USD |
| Operating expenses | 11.91M USD | 11.78M USD | 13.64M USD | 15.31M USD | 12.01M USD |
| Interest expense | 73K USD | 74K USD | 18K USD | 12K USD | 20K USD |
| Depreciation and amortization | 1.75M USD | 1.51M USD | 1.52M USD | 1.52M USD | 1.44M USD |
| Operating income | −1.2M USD | −4.22M USD | −7.62M USD | −12.8M USD | −9.61M USD |
| Net income | −363K USD | −4.29M USD | −5.85M USD | −12.2M USD | −8.55M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Sep 22, 2023 | 1:20 | — | — |
Stock split | Apr 29, 2019 | 1:15 | — | — |
Stock split | Jun 13, 2017 | 1:30 | — | — |
Stock split | Jan 28, 2014 | 1:12 | — | — |
Effective Sep 22, 2023
1:20
Effective Apr 29, 2019
1:15
Effective Jun 13, 2017
1:30
Effective Jan 28, 2014
1:12
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI965.94K0.00%2.3T USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF489.97K0.00%95.4B USD0.05%$235+0.80%
iShares Micro-Cap ETFIWC118.45K0.01%1.32B USD0.60%$183+0.11%
U.S. Micro Cap Portfolio ETFDFMC60.67K0.00%7.56B USD0.43%$57.813+0.20%
Dimensional - US Small Cap ETFDFAS41.3K0.00%33.87B USD0.31%$78.35+0.32%
Dimensional - US Sustainability Core 1 ETFDFSU23.38K0.00%2.39B USD0.15%$48.11+0.48%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR16.88K0.00%45.59B USD0.17%$84.44+0.44%
Dimensional - US Core Equity 2 ETFDFAC13.43K0.00%88.6B USD0.21%$45.33+0.49%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCDimensional - US Small Cap ETFDFASDimensional - US Sustainability Core 1 ETFDFSUU.S. Core Equity 1 Portfolio ETF Class SharesDCORDimensional - US Core Equity 2 ETFDFACAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
